Damian Jaggi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Damian Jaggi has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Florian Moritz Heussen
Department of Ophthalmology, Inselspital, University Hospital Bern, Bern, Switzerland
5 shared publications - Martin Sebastian Zinkernagel
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
5 shared publications Martin S. Zinkernagel
3 shared publicationsLieselotte E. Berger
Department of Ophthalmology, Inselspital, Bern University Hospital University of Bern Bern Switzerland
2 shared publications- Marion R. Munk
Inselspital, University Hospital Bern, Bern, Switzerland
2 shared publications - Sebastian Wolf
Bern Photographic Reading Center, Department of Ophthalmology, University Hospital, University of Bern, Bern, Switzerland
2 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Retina
- Vol. 46 (11) , 2026-2032
AI-ASSISTED OCT BIOMARKER QUANTIFICATION REVEALS DISTINCT RETINAL FLUID TRAJECTORIES IN CENTRAL RETINAL VEIN OCCLUSION
Purpose: To characterize longitudinal patterns of intraretinal (IRF) and subretinal fluid (SRF) dynamics using artificial intelligence–assisted optical coherence tomography (OCT) biomarker quantification and to evaluate their association with long-term visual outcomes in eyes with central retinal vein occlusion (CRVO). Methods: Patients with previously treatment-naïve CRVO and a documented 24-month follow-up were retrospectively included. All eyes received intravitreal aflibercept administered according to a treat-and-extend protocol. Spectral-domain OCT scans were analyzed at baseline and after 3 and 24 months. IRF and SRF volumes were quantified using RetinAI Discovery OCT Biomarker Detector (Ikerian AG). Linear regression models were used to assess the association between fluid volumes and 24-month corrected distance visual acuity (CDVA). Patients were clustered according to their IRF trajectories over time to identify distinct fluid-response phenotypes. Results: Out of 173 patients, 64 eyes (64 patients) were included. Baseline IRF and SRF volumes showed no significant association with 24-month CDVA. Cluster analysis of longitudinal IRF trajectories identified four distinct fluid-response patterns. Eyes with low or rapidly resolving IRF achieved the best long-term visual outcomes (median CDVA 73 letters), whereas those with persistent or recurrent IRF showed poorer outcomes (median 53 letters; P = 0.008). Early IRF resolution tended to predict superior visual recovery at 24 months. Conclusion: Artificial intelligence–based volumetric OCT analysis suggests that distinct retinal fluid trajectories in CRVO may have prognostic implications for long-term visual acuity, although these findings are preliminary and require validation. Dynamic IRF resolution patterns may be more informative than static fluid volumes for predicting functional outcomes after anti–vascular endothelial growth factor therapy.
- 1 November 2026
- Published by Wolters Kluwer Health in Retina
- Vol. 46 (11) , 2026-2032
AI-ASSISTED OCT BIOMARKER QUANTIFICATION REVEALS DISTINCT RETINAL FLUID TRAJECTORIES IN CENTRAL RETINAL VEIN OCCLUSION
Purpose: To characterize longitudinal patterns of intraretinal (IRF) and subretinal fluid (SRF) dynamics using artificial intelligence–assisted optical coherence tomography (OCT) biomarker quantification and to evaluate their association with long-term visual outcomes in eyes with central retinal vein occlusion (CRVO). Methods: Patients with previously treatment-naïve CRVO and a documented 24-month follow-up were retrospectively included. All eyes received intravitreal aflibercept administered according to a treat-and-extend protocol. Spectral-domain OCT scans were analyzed at baseline and after 3 and 24 months. IRF and SRF volumes were quantified using RetinAI Discovery OCT Biomarker Detector (Ikerian AG). Linear regression models were used to assess the association between fluid volumes and 24-month corrected distance visual acuity (CDVA). Patients were clustered according to their IRF trajectories over time to identify distinct fluid-response phenotypes. Results: Out of 173 patients, 64 eyes (64 patients) were included. Baseline IRF and SRF volumes showed no significant association with 24-month CDVA. Cluster analysis of longitudinal IRF trajectories identified four distinct fluid-response patterns. Eyes with low or rapidly resolving IRF achieved the best long-term visual outcomes (median CDVA 73 letters), whereas those with persistent or recurrent IRF showed poorer outcomes (median 53 letters; P = 0.008). Early IRF resolution tended to predict superior visual recovery at 24 months. Conclusion: Artificial intelligence–based volumetric OCT analysis suggests that distinct retinal fluid trajectories in CRVO may have prognostic implications for long-term visual acuity, although these findings are preliminary and require validation. Dynamic IRF resolution patterns may be more informative than static fluid volumes for predicting functional outcomes after anti–vascular endothelial growth factor therapy.
- Open Access
- 24 October 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-10
Baseline OCT-features predicting retinal atrophy in optic disc swelling
Purpose: To assess optical coherence tomography (OCT) biomarkers at initial presentation of optic disc swelling (ODS) in predicting retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) atrophy using volumetric macular and optic nerve head (ONH) analysis. Methods: In this retrospective study, patients with first-episode ODS and 6- and 12-month follow-up were included. Spectral-domain OCT (SD-OCT) volumetric scans of the macula and ONH were analysed using an AI-based platform (Discovery). Macular RNFL, ganglion cell-inner plexiform layer (GCL + IPL), and ONH RNFL volumes were quantified across ETDRS grid fields. Longitudinal change was modelled with linear mixed-effects models; predictors of 12-month outcomes were identified by multiple linear regression. Results: Fifty-two eyes from 32 patients (mean age 39 ± 13.8 years) were analysed across papilloedema ( n = 24), uveitic disc oedema ( n = 22), ischaemic ( n = 4), and infiltrative ( n = 2) aetiologies. At baseline, uveitic disc oedema eyes showed significantly higher macular RNFL and GCL + IPL volumes than papilloedema, while ONH RNFL was similarly elevated. All OCT parameters declined significantly over 12months, with greater macular loss in uveitic disc oedema cases ( p < 0.001). GCL + IPL reduction was more pronounced in the uveitic disc oedema group (− 296 ± 241 nL vs. − 110 ± 160 nL) and persisted beyond 6 months only in this group ( p = 0.012). Baseline GCL + IPL volume strongly predicted 12-month GCL + IPL volume loss (β = 0.91, p < 0.001), and worse baseline visual acuity independently predicted more severe GCL + IPL volume loss (β=-317, p = 0.002). ONH RNFL did not predict visual outcomes. Conclusion: ODS is associated with measurable structural change over 12 months. Baseline macular OCT biomarkers, particularly GCL + IPL, predicted 12-month outcomes largely independent of aetiology, and macular OCT may aid risk stratification alongside aetiological diagnosis.
- 24 October 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-10
Open AccessBaseline OCT-features predicting retinal atrophy in optic disc swelling
Purpose: To assess optical coherence tomography (OCT) biomarkers at initial presentation of optic disc swelling (ODS) in predicting retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) atrophy using volumetric macular and optic nerve head (ONH) analysis. Methods: In this retrospective study, patients with first-episode ODS and 6- and 12-month follow-up were included. Spectral-domain OCT (SD-OCT) volumetric scans of the macula and ONH were analysed using an AI-based platform (Discovery). Macular RNFL, ganglion cell-inner plexiform layer (GCL + IPL), and ONH RNFL volumes were quantified across ETDRS grid fields. Longitudinal change was modelled with linear mixed-effects models; predictors of 12-month outcomes were identified by multiple linear regression. Results: Fifty-two eyes from 32 patients (mean age 39 ± 13.8 years) were analysed across papilloedema ( n = 24), uveitic disc oedema ( n = 22), ischaemic ( n = 4), and infiltrative ( n = 2) aetiologies. At baseline, uveitic disc oedema eyes showed significantly higher macular RNFL and GCL + IPL volumes than papilloedema, while ONH RNFL was similarly elevated. All OCT parameters declined significantly over 12months, with greater macular loss in uveitic disc oedema cases ( p < 0.001). GCL + IPL reduction was more pronounced in the uveitic disc oedema group (− 296 ± 241 nL vs. − 110 ± 160 nL) and persisted beyond 6 months only in this group ( p = 0.012). Baseline GCL + IPL volume strongly predicted 12-month GCL + IPL volume loss (β = 0.91, p < 0.001), and worse baseline visual acuity independently predicted more severe GCL + IPL volume loss (β=-317, p = 0.002). ONH RNFL did not predict visual outcomes. Conclusion: ODS is associated with measurable structural change over 12 months. Baseline macular OCT biomarkers, particularly GCL + IPL, predicted 12-month outcomes largely independent of aetiology, and macular OCT may aid risk stratification alongside aetiological diagnosis.
- Open Access
- 17 June 2026
- Published by Elsevier in AJO International
- Vol. 3 (3)
Near real-time monitoring of intravitreal injection outcomes using an epic-integrated ophthalmology data mart
- 17 June 2026
- Published by Elsevier in AJO International
- Vol. 3 (3)
Open AccessNear real-time monitoring of intravitreal injection outcomes using an epic-integrated ophthalmology data mart
- Open Access
- 1 April 2026
- Published by Elsevier in AJO International
- Vol. 3 (2)
Eligibility criteria in RCTs of anti-VEGF therapy for diabetic macular edema: A systematic review
- 1 April 2026
- Published by Elsevier in AJO International
- Vol. 3 (2)
Open AccessEligibility criteria in RCTs of anti-VEGF therapy for diabetic macular edema: A systematic review
- Open Access
- 9 October 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (4) , 440-445
Evaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit
Background/aims To find biomarkers on OCT-angiography (OCT-A) that indicate a higher risk of recurrence in neovascular age-related macular degeneration (nAMD) patients before anti-vascular endothelial growth factor (anti-VEGF) therapy termination. Methods Retrospective, observational study. Stable, inactive nAMD patients who had been treated with a treat-and-extend regimen and met the predefined exit criteria were included. The macular neovascularisation (MNV) lesion was imaged on OCT-A. Lesion area, vessel density (VD), fractal dimension and height of feeder vessel were quantified. Patients with disease recurrence after termination were compared with those who stayed inactive. Results Out of 819 eyes diagnosed with nAMD and 281 with a 2-year follow-up, 77 (27.4%) reached the exit criteria. Thirty-four eyes of 33 (15 female) patients with reliable OCT-A were further analysed. Mean age was 80.35 (±9.29) years, the number of injections was 16.68 (±8.22). Treatment duration before exit was 36.15 (±16.63) months. After exit, 23 eyes stayed inactive for a follow-up period of 23.00 (±16.18) months, and 11 experienced recurrence after 13.36 (±9.90) months. VD was significantly higher in the recurrent versus inactive group with 0.60 (±0.15) versus 0.47 (±0.11), p=0.015. There was an insignificant tendency for the protective properties of type 1 MNV and a low feeder vessel. Conclusion OCT-A is useful in the risk calculation for recurrence in patients who are about to discontinue anti-VEGF treatments in nAMD. Patients with a high VD might need closer follow-ups or continued anti-VEGF treatments even if inactive.
- 9 October 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (4) , 440-445
Open AccessEvaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit
Background/aims To find biomarkers on OCT-angiography (OCT-A) that indicate a higher risk of recurrence in neovascular age-related macular degeneration (nAMD) patients before anti-vascular endothelial growth factor (anti-VEGF) therapy termination. Methods Retrospective, observational study. Stable, inactive nAMD patients who had been treated with a treat-and-extend regimen and met the predefined exit criteria were included. The macular neovascularisation (MNV) lesion was imaged on OCT-A. Lesion area, vessel density (VD), fractal dimension and height of feeder vessel were quantified. Patients with disease recurrence after termination were compared with those who stayed inactive. Results Out of 819 eyes diagnosed with nAMD and 281 with a 2-year follow-up, 77 (27.4%) reached the exit criteria. Thirty-four eyes of 33 (15 female) patients with reliable OCT-A were further analysed. Mean age was 80.35 (±9.29) years, the number of injections was 16.68 (±8.22). Treatment duration before exit was 36.15 (±16.63) months. After exit, 23 eyes stayed inactive for a follow-up period of 23.00 (±16.18) months, and 11 experienced recurrence after 13.36 (±9.90) months. VD was significantly higher in the recurrent versus inactive group with 0.60 (±0.15) versus 0.47 (±0.11), p=0.015. There was an insignificant tendency for the protective properties of type 1 MNV and a low feeder vessel. Conclusion OCT-A is useful in the risk calculation for recurrence in patients who are about to discontinue anti-VEGF treatments in nAMD. Patients with a high VD might need closer follow-ups or continued anti-VEGF treatments even if inactive.
- Open Access
- 6 May 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 103 (6) , e385-e393
Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)—A non‐inferiority, randomized controlled trial
Purpose: This trial evaluated the noninferiority of a relaxed compared to a strict treat‐and‐extend treatment strategy in patients with neovascular Age‐related macular degeneration (AMD).Methods: Multicenter, randomized, controlled, phase IV, non‐inferiority clinical trial. Patients with treatment‐naïve nAMD were randomized 1:1 to a relaxed or strict treat‐and‐extend treatment regimen. Aflibercept 2 mg/0.05 mL was used. In the relaxed regimen, up to 100 μm subfoveal subretinal fluid was tolerated, vs. no tolerance of any fluid in the strict regimen. The primary outcome was the change in best corrected visual acuity (BCVA; ETDRS letters) from baseline to the end of the study at week 104 and its difference between the two treatment arms, with a 5‐letter non‐inferiority margin.Results: We randomized 150 patients. The full analysis showed non‐inferiority of the relaxed treatment, with a mean difference of −0.12 letters (95%‐CI: −3.45 to infinity, H0; mean. diff. ≤ 5 letters: p = 0.008), and a visual acuity gain of 7.3 (4.82; 9.78) vs. 7.01 (3.67; 10.36) letters in the strict vs. relaxed regimen, respectively. Many patients deviated from the protocol due to Covid‐19. Per‐protocol analysis showed a mean difference of −1.78 letters (95%‐CI: −6.61 to infinity, H0; mean. diff. ≤ 5 letters: p = 0.136). Fewer injections were needed in the relaxed regimen, with a mean difference of −2.34 (95%‐CI: −4.11 to −0.56, p = 0.01).Conclusion: Tolerating up to 100 μm subfoveal subretinal fluid achieves good visual outcomes in our 24‐month follow‐up period, in patients treated with aflibercept for nAMD, with significantly fewer injections needed.
- 6 May 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 103 (6) , e385-e393
Open AccessComparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)—A non‐inferiority, randomized controlled trial
Purpose: This trial evaluated the noninferiority of a relaxed compared to a strict treat‐and‐extend treatment strategy in patients with neovascular Age‐related macular degeneration (AMD).Methods: Multicenter, randomized, controlled, phase IV, non‐inferiority clinical trial. Patients with treatment‐naïve nAMD were randomized 1:1 to a relaxed or strict treat‐and‐extend treatment regimen. Aflibercept 2 mg/0.05 mL was used. In the relaxed regimen, up to 100 μm subfoveal subretinal fluid was tolerated, vs. no tolerance of any fluid in the strict regimen. The primary outcome was the change in best corrected visual acuity (BCVA; ETDRS letters) from baseline to the end of the study at week 104 and its difference between the two treatment arms, with a 5‐letter non‐inferiority margin.Results: We randomized 150 patients. The full analysis showed non‐inferiority of the relaxed treatment, with a mean difference of −0.12 letters (95%‐CI: −3.45 to infinity, H0; mean. diff. ≤ 5 letters: p = 0.008), and a visual acuity gain of 7.3 (4.82; 9.78) vs. 7.01 (3.67; 10.36) letters in the strict vs. relaxed regimen, respectively. Many patients deviated from the protocol due to Covid‐19. Per‐protocol analysis showed a mean difference of −1.78 letters (95%‐CI: −6.61 to infinity, H0; mean. diff. ≤ 5 letters: p = 0.136). Fewer injections were needed in the relaxed regimen, with a mean difference of −2.34 (95%‐CI: −4.11 to −0.56, p = 0.01).Conclusion: Tolerating up to 100 μm subfoveal subretinal fluid achieves good visual outcomes in our 24‐month follow‐up period, in patients treated with aflibercept for nAMD, with significantly fewer injections needed.
- Open Access
- 19 February 2025
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 38, 102286
Branch retinal artery occlusion in a young woman with papilledema and a prepapillary vascular loop
- 19 February 2025
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 38, 102286
Open AccessBranch retinal artery occlusion in a young woman with papilledema and a prepapillary vascular loop
- Open Access
- 1 February 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (7) , 645-654
Standardization of OCT Angiography Nomenclature in Retinal Vascular Diseases
- 1 February 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (7) , 645-654
Open AccessStandardization of OCT Angiography Nomenclature in Retinal Vascular Diseases
- Open Access
- 1 January 2025
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 16 (1) , 207-214
Choroidal Thickening and Outer Retinal Alterations in Vitamin A Deficiency: A Case Report
Introduction: Retinal alterations in vitamin A deficiency have been described. The purpose of this study was to report a case of retinal alterations and choroidal thickening due to proven vitamin A deficiency. Case Presentation: We report a case of a 39-year-old woman who presented with progressing nyctalopia and mildly reduced visual acuity over a period of 1–2 years, despite being on oral vitamin A supplementation, following a history of gastric bypass and biliopancreatic diversion surgeries many years ago. Vitamin A levels were severely reduced (<0.1 µmol/L, reference range: 1.05–2.08 µmol/L). The outer retinal layers exhibited structural alterations and a reduction in thickness, while choroidal thickness was increased. The electroretinogram showed complete depletion of scotopic responses and a mild reduction in photopic responses. After intravenous vitamin A supplementation, complete resolution of both functional and structural changes was achieved. Conclusion: This case highlights the importance of considering vitamin A deficiency even in patients receiving ongoing oral vitamin A supplementation, particularly if symptoms and clinical findings suggest its presence. Choroidal thickening and outer retinal thinning may provide further insights into the pathophysiology of this condition in future analyses.
- 1 January 2025
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 16 (1) , 207-214
Open AccessChoroidal Thickening and Outer Retinal Alterations in Vitamin A Deficiency: A Case Report
Introduction: Retinal alterations in vitamin A deficiency have been described. The purpose of this study was to report a case of retinal alterations and choroidal thickening due to proven vitamin A deficiency. Case Presentation: We report a case of a 39-year-old woman who presented with progressing nyctalopia and mildly reduced visual acuity over a period of 1–2 years, despite being on oral vitamin A supplementation, following a history of gastric bypass and biliopancreatic diversion surgeries many years ago. Vitamin A levels were severely reduced (<0.1 µmol/L, reference range: 1.05–2.08 µmol/L). The outer retinal layers exhibited structural alterations and a reduction in thickness, while choroidal thickness was increased. The electroretinogram showed complete depletion of scotopic responses and a mild reduction in photopic responses. After intravenous vitamin A supplementation, complete resolution of both functional and structural changes was achieved. Conclusion: This case highlights the importance of considering vitamin A deficiency even in patients receiving ongoing oral vitamin A supplementation, particularly if symptoms and clinical findings suggest its presence. Choroidal thickening and outer retinal thinning may provide further insights into the pathophysiology of this condition in future analyses.
- Open Access
- 24 August 2024
- Published by BMJ in BMJ Open Ophthalmology
- Vol. 9 (1) , e001659
Aflibercept for central retinal vein occlusions: long-term outcomes of a ‘Treat-and-Extend’ regimen
Background/aims This study reports on the long-term functional and anatomical outcomes of patients with central retinal vein occlusion (CRVO) treated under the Bern treat-and-extend (T&E) protocol. Methods Observational study. Treatment-naive patients with CRVO and consecutive macular oedema treated with aflibercept were included. The T&E protocol involved 2 monthly injections followed by an extension based on individual assessments. At each visit, best-corrected visual acuity (BCVA), optical coherence tomography imaging and a 2 mg aflibercept injection were administered. Changes in BCVA, proportion of patients gaining ≥15 letters, central subfield thickness (CST) and treatment intervals were analysed. Results Out of 173 patients, 64 had a follow-up of at least 2 years. BCVA improved from 46.7±25.3 at baseline to 78.3±0.5 at year 9. The proportion of patients with ≥15 letters gained was 56%, 53%, 56%, 62%, 52%, 52%, 43%, 50% and 33% at years 1–9, respectively. CST decreased significantly from 660±242 µm at baseline to 359±63 µm at year 9. Treatment intervals extended from 4 weeks initially to an average of 13.0±4.1 weeks by year 8. Conclusions The T&E regimen for CRVO shows sustained visual improvements and reduced CST over time. Patients maintained stable visual gains for many years, demonstrating the effectiveness of this treatment approach. However, no control group was available to compare our T&E regimen with other strategies.
- 24 August 2024
- Published by BMJ in BMJ Open Ophthalmology
- Vol. 9 (1) , e001659
Open AccessAflibercept for central retinal vein occlusions: long-term outcomes of a ‘Treat-and-Extend’ regimen
Background/aims This study reports on the long-term functional and anatomical outcomes of patients with central retinal vein occlusion (CRVO) treated under the Bern treat-and-extend (T&E) protocol. Methods Observational study. Treatment-naive patients with CRVO and consecutive macular oedema treated with aflibercept were included. The T&E protocol involved 2 monthly injections followed by an extension based on individual assessments. At each visit, best-corrected visual acuity (BCVA), optical coherence tomography imaging and a 2 mg aflibercept injection were administered. Changes in BCVA, proportion of patients gaining ≥15 letters, central subfield thickness (CST) and treatment intervals were analysed. Results Out of 173 patients, 64 had a follow-up of at least 2 years. BCVA improved from 46.7±25.3 at baseline to 78.3±0.5 at year 9. The proportion of patients with ≥15 letters gained was 56%, 53%, 56%, 62%, 52%, 52%, 43%, 50% and 33% at years 1–9, respectively. CST decreased significantly from 660±242 µm at baseline to 359±63 µm at year 9. Treatment intervals extended from 4 weeks initially to an average of 13.0±4.1 weeks by year 8. Conclusions The T&E regimen for CRVO shows sustained visual improvements and reduced CST over time. Patients maintained stable visual gains for many years, demonstrating the effectiveness of this treatment approach. However, no control group was available to compare our T&E regimen with other strategies.